Mankind Pharma Share Price in Focus; Board Approves Subsidiary Divestment and Netherlands Expansion

Mankind Pharma Limited has approved two strategic proposals aimed at sharpening its business focus and strengthening its global research footprint. 

The company's board has cleared the sale of its wholly owned subsidiary, Broadway Hospitality Services Private Limited, while also approving the incorporation of a wholly owned subsidiary in the Netherlands to support research and business development activities.  

Board Clears Divestment of Hospitality Subsidiary 

As part of its strategy to exit non-core businesses, Mankind Pharma will divest its entire stake in Broadway Hospitality Services Private Limited. 

The company has approved the sale of its 100% shareholding in the subsidiary to AKRK Projects LLP and its partners for a total consideration of ₹49 crore, subject to closing adjustments. The transaction is expected to be completed within 90 days.  

Broadway Contributed a Small Portion of Financials 

Broadway Hospitality Services contributed only a limited share to Mankind Pharma's overall financial performance during FY26. 

For the year ended March 31, 2026, the subsidiary reported ₹9.63 crore in revenue, ₹9.90 crore in total income, and a net worth of ₹38.99 crore, accounting for 0.07% of revenue and 0.24% of the company's net worth.  

Netherlands Subsidiary Approved 

The board has also approved the incorporation of a wholly owned subsidiary in the Netherlands. 

The new entity will function as a Special Purpose Vehicle (SPV) to hold investments in research and development assets while undertaking business development activities focused on niche therapies through strategic investments, acquisitions or joint ventures.  

Up to €5 Million Investment Planned 

Mankind Pharma plans to invest up to €5 million in the proposed Netherlands subsidiary through one or more tranches. 

The investment will be used to fund the entity's establishment, operating expenses, procurement activities and future investments. Mankind Pharma will hold 100% ownership in the subsidiary through subscriptions to its equity or other eligible securities.  

Read More: Sterlite Technologies Wins European Patent Dispute Against Fujikura; EPO Revokes Patent! 

Mankind Pharma Share Price Performance 

As of 10 July 2026, Mankind Pharma share price was closed at ₹2,528.00 per share, reflecting a decline of 0.16 from the previous trading session. 

Conclusion 

Mankind Pharma has taken two strategic decisions by exiting a non-core hospitality business and expanding its international presence through a wholly owned subsidiary in the Netherlands. While the divestment will streamline the company's portfolio, the proposed overseas entity is expected to support its long-term R&D and niche therapy growth strategy.  

Want to read stock market updates in Hindi? Angel One News gives comprehensive share market news in Hindi. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

 Investments in the securities market are subject to market risks, read all the related documents carefully before investing.